课题基金 / 基金详情

Recombinant Sendai Virus as a Novel HIV Vaccine Vector

Recombinant Sendai Virus as a Novel HIV Vaccine Vector
重组仙台病毒作为新型 HIV 疫苗载体
批准号:
6696129
负责人:
Karen S Slobod
金额:
$22.5万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2005-07-31

项目摘要

项目成果

Karen S Slobod的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-term objective of this project is to prepare and characterize an effective, live virus vaccine candidate for HIV. A successful HIV vaccine should be easily produced, administered and should trigger potent and durable B and T cell responses. The murine parainfluenza type 1 virus (Sendal virus; SV) is a member of the Paramyxovirus family which can be manipulated through reverse genetics to deliver HIV envelope glycoproteins. This murine virus is likely to prove an excellent vaccine vector based on preliminary results from our current human trials examining SV as a vaccine for human parainfluenza virus type 1 and our studies indicating the potent immunogenicity of intranasal SV and SV recombinants (rSV). We further suggest that intranasal administration of SV-based vaccines will prove to be a facile and effective means of priming systemic and mucosal immune responses against HIV. In this focused application we propose the following two aims to meet our objectives of characterizing the immune potential of SV-based HIV vaccines: Aim 1: To examine mucosal and systemic B cell responses elicited by intransasal recombinant SV expressing HIV envelope protein (rSV-env). Aim 2: To examine CD4 + and CD8 + T cell responses elicited by intransasal rSV-env. It is expected that as a live virus vaccine, rSV-env will elicit strong and durable B and T cell responses, to be evaluated in the two specific aims. Unique attributes of rSV which predict the success of this vaccine vector include the capacity to expand rSV to enormous titer in eggs (an FDA-approved culture system for human vaccines), easy administration by the intranasal route (obviating requirement for sterile syringes and needles and a route capable of inducing mucosal IgA) and the capacity to elicit potent and stable B and T cell responses. Studies described in this application may ultimately identify rSV as an effective intranasal vaccine vehicle useful in the prevention of HIV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical and Primate Paramyxovirus Vaccine Evaluation
Recombinant Sendai Virus as a Novel HIV Vaccine Vector
CLINICAL EVALUATION OF A MULTI-ENVELOPE AIDS VACCINE
CLINICAL EVALUATION OF A MULTI-ENVELOPE AIDS VACCINE
海外基金